Phase II Randomized Study of High Dose Interleukin-2 Versus Stereotactic Body Radiation (SBRT) and High Dose Interleukin-2 (IL-2) in Patients With Metastatic Melanoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Interleukin-2 (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms SBRT-IL2
- 16 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 18 Sep 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated